CoChat

Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits

Open access

The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.

Abstract

T ype 2 diabetes is a complex meta-bolic disorder characterized byhyperglycemia arising from a com-bination of insufficient insulin secretion together with resistance to insulin action. The incidence and prevalence of type 2 diabetes are rising steadily, fuelled in part by a concomitant increase in the world-wide rates of obesity. As longitudinal studies of type 2 diabetes provide evi-dence linking improved glycemic control with a reduction in the rates of diabetes-associated complications, there is consid-erable interest in the therapy of type 2 diabetes (Fig. 1), with a focus on the de-velopment and use of new agents that ex-hibit improved efficacy and safety relative

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc09-1499

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Relative comparison of properties exhibited by different classes of agents approved for the treatment of type 2 diabetes. CVD, cardiovascular disease; TG, triglycerides; CHF, congestive heart failure. A1C reduction depends on starting A1C.
Figure 1 Relative comparison of properties exhibited by different classes of agents approved for the treatment of type 2 diabetes. CVD, cardiovascular disease; TG, triglycerides; CHF, congestive heart failure. A1C reduction depends on starting A1C.CC BY-NC-ND · PubMed Central
Figure 2 Comparison of features associated with exenatide twice daily versus the properties of the emerging class of long-acting GLP-1R agonists that achieve more prolonged and sustained GLP-1R activation. CVD, cardiovascular disease.
Figure 2 Comparison of features associated with exenatide twice daily versus the properties of the emerging class of long-acting GLP-1R agonists that achieve more prolonged and sustained GLP-1R activation. CVD, cardiovascular disease.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Research works printed but not linked: 2

  1. Horner, SEER Cancer Statistics Review, 1975–2006 [Internet], 2009
  2. Parola, 2009, FDA Advisory Committee Nonclinical Briefing Document, NDA, 22

Cited by

Items 101–200 of 321

Metadata

Authors
Drucker, D. J., Sherman, S. I., Gorelick, F. S., Bergenstal, R. M., Sherwin, R. S., & Buse, J. B.
Affiliations
  • University of Toronto (CA)
  • The University of Texas MD Anderson Cancer Center (US)
  • Yale University (US)
  • Park Nicollet Health Services (US)
  • University of North Carolina at Chapel Hill (US)
Corresponding author
Drucker, Daniel J.
Venue
Diabetes Care
Published
2010-02-01
Volume
33
Issue
2
Pages
428-433
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2134760433
Cited by
316
References
40
Citations by year
2026: 10 · 2025: 10 · 2024: 10 · 2023: 10 · 2022: 13 · 2021: 15 · 2020: 11 · 2019: 17 · 2018: 17 · 2017: 15 · 2016: 20 · 2015: 24 · 2014: 28 · 2013: 33 · 2012: 31
FWCI
28.47
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • V Foundation for Cancer Research
  • Park Nicollet Foundation
  • Amgen
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • GlaxoSmithKline
  • Sanofi
  • Celgene
  • F. Hoffmann-La Roche
  • Exelixis
  • Insulet Corporation
  • MannKind Corporation
  • ResMed
  • Eisai
  • Novo Nordisk
  • Plexxikon
  • National Institutes of Health
  • National Cancer Institute
  • National Institute of Diabetes and Digestive and Kidney Diseases (T32DK007017)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
type 2 diabetes, incretin-based therapy, GLP-1 receptor agonists, DPP-4 inhibitors, glycemic control, insulin resistance, insulin secretion, diabetes complications, drug safety, obesity
MeSH terms
Exenatide, Diabetes Mellitus, Type 2, Drug Administration Schedule, Humans, Hypoglycemic Agents, Peptides, Venoms, Incidence, Prevalence, Treatment Outcome, Risk Assessment, Glucagon-Like Peptide 1, Incretins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.